浏览全部资源
扫码关注微信
Research progress on
Pithecellobium clypearia as antibiotic adjuvants- Acta Scientiarum Naturalium Universitatis Sunyatseni Vol. 59, Issue 4, Pages: 1-6(2020)
- 作者机构：
中山大学生命科学学院/广东省中药上市后质量与药效再评价工程技术研究中心/ 广东省热带亚热带植物资源重点实验室，广东 广州 510275
- 作者简介：
- 基金信息：
DOI：10.13471/j.cnki.acta.snus.2020.04.09.2020E008
CLC： R28Published：20 July 2020，
Received：13 April 2020，
扫 描 看 全 文
刘翀,王永刚,李沛波等.南药猴耳环作为抗生素佐剂的研究进展[J].中山大学学报(自然科学版),2020,59(04):1-6.
LIU Chong,WANG Yonggang,LI Peibo,et al.Research progress on Pithecellobium clypearia as antibiotic adjuvants[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2020,59(04):1-6.
刘翀,王永刚,李沛波等.南药猴耳环作为抗生素佐剂的研究进展[J].中山大学学报(自然科学版),2020,59(04):1-6. DOI： 10.13471/j.cnki.acta.snus.2020.04.09.2020E008.
LIU Chong,WANG Yonggang,LI Peibo,et al.Research progress on Pithecellobium clypearia as antibiotic adjuvants[J].Acta Scientiarum Naturalium Universitatis Sunyatseni,2020,59(04):1-6. DOI： 10.13471/j.cnki.acta.snus.2020.04.09.2020E008.
摘要
本研究团队近年来致力于传统中药新功能开发，从多种中药中筛选出一种具有显著抗生素增效作用的岭南传统中药——猴耳环(
Pithecellobium clypearia
），其有作为抗生素佐剂的潜力。本文从细菌抗生素耐药现状分析、抗生素佐剂的研究进展以及猴耳环作为抗生素佐剂的研究进展这三个方面，结合本团队的研究成果，对猴耳环作为抗生素佐剂的现状作综述，以期为相关研究提供参考。
Abstract
In recent years
our team has been committed to the research of new functions of traditional Chinese medicine
and systematically screened Chinese medicines and identified
Pithecellobium clypearia
with significant antibiotic synergistic effect
which has the potential to be used as an antibiotic adjuvant. In this review
we summarized the current situation of bacterial antibiotic resistance
the research progress of antibiotic adjuvant
and the research progress of
Pithecellobium clypearia
as antibiotic adjuvant to provide the reference for the further investigation and development of this herbal plant.
关键词
抗生素多重耐药抗生素佐剂猴耳环(Pithecellobium clypearia）协同增效
Keywords
multiple antibiotic resistanceantibiotic adjuvantPithecellobium clypeariasynergistic effect
references
TROUILLER P, OLLIARO P L. Drug development output from 1975 to 1996: What proportion for tropical diseases? [J]. International Journal of Infectious Diseases, 1999, 3(2):61-63.
GARDNER P S, STANFIELD J P, WRIGHT A E, et al. Viruses, bacteria, and respiratory disease in children [J]. British Medical Journal, 1960, 1: 1077-1081.
FLEMING A. The discovery of penicillin [J]. British Medical Journal, 1944, 2(1): 792-799.
ERIKSEN K R. "Celbenin"-resistant staphylococci [J]. Ugeskrift for Laeger, 1961, 1: 384-386.
GANDRA S, CHOI J H, McELVANIA E, et al. Faropenem resistance causes in vitro cross resistance to carbapenems in ESBL-producing Escherichia coli[J]. International Journal of Antimicrobial Agents, 2020: 105902.
BAYM M, LIEBERMAN T D, KELSIC E D, et al. Spatiotemporal microbial evolution on antibiotic landscapes[J]. Science, 2016, 353(6304): 1147-1151.
KALAN L, WRIGHT G D. Antibiotic adjuvants: Multicomponent anti-infective strategies [J]. Expert Reviews in Molecular Medicine, 2011, 13(13): e5.
GILL E E, FRANCO O L, HANCOCK R E W. Antibiotic adjuvants: diverse strategies for controlling drug‐resistant pathogens [J]. Chemical Biology & Drug Design, 2015, 85(1): 56-78.
ABREU A C, COQUEIRO A, SULTAN A R, et al. Looking to nature for a new concept in antimicrobial treatments: isoflavonoids from Cytisus striatus as antibiotic adjuvants against MRSA [J]. Science Reports, 2017, 7(1): 3777-3781.
ENRIGHT M C, ROBINSON D A, RANDLE G, et al. The evolutionary history of methicillin-resistant Staphylococcus aureus (MRSA) [J]. Proceedings of the National Academy of Sciences, 2002, 99(11): 7687-7692.
PEREZ F, ENDIMIANI A, HUJER K M, et al. The continuing challenge of ESBLs [J]. Current Opinion in Pharmacology, 2007, 7(5): 459-469.
GOLDRICK B. First reported case of VRSA in the United States: An alarming development in microbial resistance [J]. American Journal of Nursing, 2002, 102(11): 17-18.
HU F P, GUO Y, ZHU D M, et al. Antimicrobial resistance profile of clinical isolates in hospitals across China: report from the CHINET Surveillance Program, 2017 [J]. Chinese Journal of Infection and Chemotherapy, 2018, 18(3): 241-251.
CHURCHYARD G J, SWINDELLS S. Controlling latent TB tuberculosis infection in high-burden countries: A neglected strategy to end TB [J]. PLoS Medicine, 2019, 16(4): e1002787.
岳磊, 牛晋国, 吉涛, 等. 饲用抗生素在畜禽养殖中的问题与对策分析 [J]. 中国猪业, 2018, 7(1): 29-31.
YUE L, NIU J G, JI T, et al. Problems and countermeasures of feeding antibiotics in livestock and poultry breeding [J].China Swine Industry, 2018, 7(1): 29-31.
BONDI A, DIETZ C C. Production of penicillinase by bacteria [J]. Experimental Biology & Medicine, 1944, 56(2): 132-134.
DURAND G A, RAOULT D, DUBOURG G. Antibiotic discovery: History, methods and perspectives [J]. International Journal of Antimicrobial Agents, 2019, 53(4): 371-382.
BROCHADO A R, TELZEROW A, BOBONIS J, et al. Species-specific activity of antibacterial drug combinations[J]. Nature, 2018, 559: 259-263.
KAREN B. Investigational agents for the treatment of gram-negative bacterial infections: a reality check [J]. American Chemical Society Infectious Diseases, 2015, 1(11): 509-511.
DAVID B. Antibiotic resistance breakers: can repurposed drugs fill the antibiotic discovery void? [J]. Nature Reviews Drug Discovery, 2015, 14(12): 821-825.
GONZÁLEZ-BELLO C. Antibiotic adjuvants – A strategy to unlock bacterial resistance to antibiotics [J]. Bioorganic & Medicinal Chemistry Letters, 2017, 27(18): 4221-4228.
CHAKRADHAR S. What's old is new: Reconfiguring known antibiotics to fight drug resistance [J]. Nature Medicine, 2016, 22(11): 1197-1199.
KING A M, KING D T, FRENCH S, et al. Structural and kinetic characterization of diazabicyclooctanes as dual inhibitors of both serine-β-lactamases and penicillin-binding proteins [J]. Acs Chemical Biology, 2016, 11(4): 864-868.
LAGACÉWIENS P, WALKTY A, KARLOWSKY J A. Ceftazidime–avibactam: an evidence-based review of its pharmacology and potential use in the treatment of Gram-negative bacterial infections [J]. Core Evidence, 2014, 1(9): 13-25.
COLEMAN K. Diazabicyclooctanes (DBOs): a potent new class of non-β-lactam β-lactamase inhibitors [J]. Current Opinion in Microbiology, 2011, 14(5): 550-555.
SCHWEIZER, P H. Understanding efflux in gram-negative bacteria: opportunities for drug discovery [J]. Expert Opinion on Drug Discovery, 2012, 7(7): 633-642.
LOU L L, LI L G, et al. 3, 3′-Neolignans from Pithecellobium clypearia Benth and their anti-inflammatory activity [J]. Fitoterapia, 2016, 112: 16-21.
BAO L, YAO X, XU J, et al. Effects of Pithecellobium clypearia Benth extract and its main components on inflammation and allergy [J]. Fitoterapia, 2009, 80(6): 349-353.
MUSLIM N, NASSAR Z D, AISHA A F. Antiangiogenesis and antioxidant activity of ethanol extracts of Pithecellobium jiringa [J]. BMC Complementary & Alternative Medicine, 2012, 12(1): 210-213.
XIE C Y, LIN L W. Study on the chemical constituents of Pithecellobium clypearia [J]. Journal of Chinese Medicinal Materials, 2011, 34(7):1060-1062.
CHEN Y. Isolation and identification of chemical constituents from Pithecellobium clypearia Bemth [J]. Applied & Environmental Microbiology, 2015, 64(9): 3175-3178.
GUO X Y, WANG N L, BAO L, et al. Chemical constituents from Pithecellobium clypearia and their effects on T lymphocytes proliferation [J]. Journal of Chinese Pharmaceutical Sciences, 2007, 16(3): 208-213.
LIU C, HUANG H, ZHOU Q, et al. Antibacterial and antibiotic synergistic activities of the extract from Pithecellobium clypearia against clinically important multidrug-resistant gram-negative bacteria [J]. European Journal of Integrative Medicine, 2019, 32:100999.
苏妙贤, 唐之岳, 黄伟欢, 等. 猴耳环化学成分研究 [J]. 中药材, 2009, 32(5): 705-707.
SU M X, TANG Z Y, HUANG W H, et al. Studies on the chemical comstituents of Pithecellobium clypearia [J]. Journal of Chinese Medicinal Materials, 2009, 32(5): 705-707.
谢春英, 林乐维. 猴耳环化学成分研究 [J]. 中药材, 2011, 33(7): 1060-1062.
XIE C Y, LIN L W. Study on the chemical constituents of Pithecellobium clypearia [J]. Journal of Chinese Medicinal Materials, 2011, 33(7): 1060-1062.
QIN R, XIAO K, LI B, et al. The combination of catechin and epicatechin callate from Fructus crataegi potentiates beta-lactam antibiotics against methicillin-resistant staphylococcus aureus (MRSA) in vitro and in vivo[J]. International Journal of Molecular Sciences, 2013, 14(1): 1802-1821.
HU Z Q, ZHAO W H, YUKIHIKO H, et al. Epigallocatechin gallate synergy with ampicillin/sulbactam against 28 clinical isolates of methicillin-resistant Staphylococcus aureus [J]. Journal of Antimicrobial Chemother, 2001, 48(3): 361-364.
KUMAR M, NEHRA K, DUHAN J. Phytochemical analysis and antimicrobial efficacy of leaf extracts of Pithecellobium dulce [J]. Asian Journal of Pharmaceutical and Clinical Research, 2013, 6(1): 70-76.
SU W W, LIU C, ZHOU Q, et al. Method of Chinese herbal medicine extract used for treating multiple diseases caused by drug resistant bacteria infection[P]. U.S Patent Application 15/920,480.
苏薇薇，刘翀，周倩，等. 猴耳环提取物在制备抗产超广谱β-内酰胺酶大肠杆菌药物中的应用:CN105998153B [P]. 2016-05-10 .
SU W W，LIU C，ZHOU Q，et al. Application of Pithecellobium clypearia in drug development against ESBLs Escherichia coli:CN105998153B [P]. 2016-05-10 .
王永刚, 刘博宇, 苏薇薇, 等. 猴耳环提取物及其在制备抗耐甲氧西林金黄色葡萄球菌药物中的应用 ：CN103385912A [P]. 2013-07-24 .
WANG Y G, LIU B Y, SU W W, et al. Application of Pithecellobium clypearia in drug development against MRSA:CN103385912A [P].2013-07-24.
李沛波，周倩，刘翀，等. 猴耳环提取物在制备抗多重耐药鲍曼不动杆菌药物中的应用:CN105816511B[P]. 2016-05-10.
LI P B, ZHOU Q, LIU C, et al. Application of Pithecellobium clypearia in drug development against multiple drug resistant Acinetobacter baumannii:CN105816511B [P]. 2016-05-10.
刘翀. S20b作为抗生素佐剂持续给药抗耐药菌药效及机制研究 [D]. 广州: 中山大学, 2019.
LIU C. Antibacterial activity and mechanism of S20b as antibiotics adjuvant with continuous treatment against drug resistance pathogens [D]. Guangzhou: Sun Yat-sen University, 2019.
CHACÓN O, FORNO N, LAPIERRE L, et al. Effect of Aloe barbadensis Miller (Aloe vera) associated with beta-lactam antibiotics on the occurrence of resistance in strains of Staphylococcus aureus and Streptococcus uberis[J]. European Journal of Integrative Medicine, 2019, 32: 100996.
SOLTANI M, LYMBERY A, SONG S K, et al. Adjuvant effects of medicinal herbs and probiotics for fish vaccines[J]. Reviews in Aquaculture, 2019, 11(4): 1325-1341.
HACIOGLU M, DOSLER S, TAN A S B, et al. Antimicrobial activities of widely consumed herbal teas, alone or in combination with antibiotics: an in vitro study[J]. Peer J, 2017, 5: e3467.
LIU C, HUANG H, ZHOU Q, et al. Pithecellobium clypearia extract enriched in gallic acid and luteolin has antibacterial activity against MRSA and reduces resistance to erythromycin, ceftriaxone sodium and levofloxacin[J]. Journal of Applied Microbiology, 2020. doi.org/10.1111/jam.14668.
吴整军. 中医药抗感染治疗的探讨[J]. 中华医院感染学杂志, 2004, 14(11): 1296-1297.
WU Z J. Anti-infective treatment with Chinese traditional medicine [J]. Chinese Journal of Nosoconmiology, 2004, 14(11): 1296-1297.
王秀莲. 中医药治疗感染病的优势与思路 [J]. 天津中医药大学学报, 2007, 26(3): 6-7.
WANG X L. Superiority and thoughts of TCM on treating infectious disease [J]. Journal of Tianjin University of Traditional Chinese Medicine, 2007, 26(3): 6-7.
王秀莲. 再论中医治疗感染性疾病的优势 [J]. 天津中医药大学学报, 2011, 30(4): 3-5.
WANG X L. Re-discussing the advantage of TCM in treating infectious diseases [J]. Journal of Tianjin University of Traditional Chinese Medicine, 2011, 30(4): 3-5.
0
Views
1
下载量
0
CSCD
- L-PDFDownload
- BibTeXDownload
- EndnoteDownload
- RefMan Download
- NoteExpressDownload
- NoteFirstDownload
Publicity Resources
Related Articles
Related Author
Related Institution
- Postal code：510275
- Tel：020-84112585，84113223 Email：xuebaozr@mail.sysu.edu.cn
- Technical support is provided by Beijing Founder electronics co., LTD 京ICP备09064830号-19
京公网安备11010802024621 - It is recommended to read the content of this site in Chrome&IE9+. Please switch to extreme mode in browser 360.
- Cookies We use cookies to help provide and enhance our service and tailor content. By continuing, you agree to the use of cookies.
